Dinutuximab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 207 publications
Role of Anti-GD2 Targeted PEG-b-PLGA Nanoparticles in the Treatment of MYCN Driven Neuroblastoma.
Journal: ACS applied bio materials
Published: April 02, 2026
Immunotherapeutic Strategies Targeting GD2-Expressing Malignancies.
Journal: Advances in experimental medicine and biology
Published: March 31, 2026
Impacts of Globo H Ceramide on Tumor Microenvironment.
Journal: Advances in experimental medicine and biology
Published: March 31, 2026
Dinutuximab-Associated Neurotoxicity: Incidence, Presentation, Risk Factors, and Nursing Interventions.
Journal: Journal of pediatric hematology/oncology nursing
Published: February 18, 2026
End-of-Induction Response and Tolerability of High-Risk Neuroblastoma Treated with Chemoimmunotherapy-Modified N7 Regimen with Dinutuximab Beta.
Journal: Cancers
Published: February 13, 2026
Dinutuximab Beta Anaphylaxis: Successful Desensitization Using a One-Bag Protocol in a Pediatric Case.
Journal: Pediatric blood & cancer
Published: December 13, 2025
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 12, 2025
Efficacy and safety of dinutuximab beta combined with GM-CSF and isotretinoin ± chemotherapy as first-line maintenance treatment for pediatric high-risk neuroblastoma in China.
Journal: Frontiers in oncology
Published: December 11, 2025
Immunotherapeutic advances in pediatric neuroblastoma: Overcoming resistance through biomarker-guided combinations.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: November 14, 2025
Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons.
Journal: Frontiers in oncology
Published: October 30, 2025
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective Study.
Journal: Pediatric blood & cancer
Published: October 03, 2025
Last Updated: 04/28/2026